diabetes

Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety

Fourth annual initiative supports World Diabetes Day 2025 with patient-led creativity and storytellingBASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes…

2 days ago

Immutheras Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz,…

3 weeks ago

ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment

LONDON, June 28, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research…

3 weeks ago

Metabolon’s Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)

Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize the treatment of type 2 diabetes MORRISVILLE, N.C.,…

3 weeks ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

1 month ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to…

1 month ago

CCS Presents Four Peer-Reviewed Posters at American Diabetes Associations 85th Scientific Sessions

CCS’s latest evidence-based research reinforces the most innovative and intelligent approaches to improving adherence and outcomes, while reducing the total…

1 month ago

Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…

1 month ago

Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…

1 month ago

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June…

1 month ago